Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support research in the pharmaceutical sector in Newbury.

The Department funds research and research infrastructure, which supports patients and the public to participate in high-quality research across the United Kingdom, through the National Institute of Health and Care Research (NIHR).

Development and delivery of research in the pharmaceutical sector is supported and enabled nationwide through NIHR infrastructure, including the NIHR Research Delivery Network (RDN), the NIHR Clinical Research Facilities (CRFs), the NIHR Biomedical Research Centres (BRCs), and the newly designated NIHR Commercial Research Delivery Centres (CRDCs). These all support the delivery of clinical research through facilities, staff resource, collaborations, and funding.

In Newbury, pharmaceutical research benefits from the South Central RDN, as well as the Oxford and Southampton-based CRFs and BRCs, and from April, a new CRDC in Southampton, all of which support a range of pharmaceutical studies in the region.

In order to maximise our potential to be a world leader and develop a more competitive, efficient, and accessible clinical research system, the Department is committed to implementing the recommendations from Lord O'Shaughnessy’s independent review of commercial clinical trials in full. We expect these efforts to attract more commercial investment in clinical research and yield a broad and diverse portfolio of clinical trials in the United Kingdom, to provide innovative treatment options for patients.